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Peptides corresponding to the foot-and-mouth disease virus VP1 G-H loop are capable of inducing neutralizing antibodies in
somespecies butareconsidered relatively poorimmunogens,especially atmucosalsurfaces.However,intranasaladministrationof
antigens alongwiththe appropriate delivery vehicle/adjuvant has been shownto induce mucosalimmuneresponses, and bacterial
enterotoxins have long been known to be eﬀective in this regard. In the current study, two diﬀerent carrier/adjuvant approaches
wereusedtoaugmentmucosalimmunitytotheFMDVO1 BFSG-Hloopepitope,inwhichtheG-Hloopwasgeneticallycoupledto
the E. coli LT-B subunit and coexpressed with the LTA2 fragment (LTA2B-GH), or the nontoxic pseudomonas exotoxin A (ntPE)
was fused to LTA2B-GH at LT-A2 to enhance receptor targeting. Only guinea pigs that were inoculated intranasally with ntPE-
LTA2B-GH and LTA2B-GH induced signiﬁcantanti-G-H loop IgA antibodies in nasalwashes at weeks 4 and 6 when compared to
ovalbumin or G-H loop immunized animals. These were also the only groups that exhibited G-H loop-speciﬁc antigen-secreting
cells in the nasal mucosa. These data demonstrate that fusion of nonreplicating antigens to LTA2B and ntPE-LTA2B has the
potential to be used as carriers/adjuvants to induce mucosalimmune responses against infectious diseases.
1.Introduction
The generation of an eﬀective mucosal immune response to
foreign proteins often requires the addition of a carrier/ad-
juvantmolecules, many ofwhich are bacterial exotoxinssuch
as cholera toxin (CT), heat-labile enterotoxin (LT), pertussis
toxin (PT), and exotoxin A (PE) secreted by Vibrio cholera,
Escherichia coli, Bordetella pertussis, and Pseudomonas aerug-
inosa, respectively. Each of these toxins possess ADP-
ribosylating activity, and their nontoxic forms can be used
as mucosal carrier adjuvants because of their ability to bind
to receptors on the epithelial cell surface, thereby, facilitating
their delivery to the underlying lymphoepithelial tissue [1].
Moreover, antitoxin responses are so potent that they gener-
ate strong immune responses against foreign molecules that
are simultaneously present at the mucosal surfaces through
ab y s t a n d e re ﬀect. It has also been shown that coadminis-
tration of foreign proteins with potent mucosal adjuvants
can prevent the induction of oral tolerance [2]. Regrettably,
widespread use of toxin-based mucosal adjuvants has been
dramatically restricted due to the inherent toxicity of these
agents [3], necessitating the development of less eﬀective
“toxoids.”
CT and LT, the most extensively studied mucosal adju-
vants in animal models to date, belong to the AB5 class of
bacterial toxins composed of a receptor-binding pentameric2 Advances in Virology
B subunit and an enzymatically active A subunit. The B sub-
unit (LT-B) is a 103-amino acid protein that self-assembles
into a 55kDa pentameric structure that is responsible for
binding to various eukaryotic cell receptors [4]. LT-B has
been found to be associated with multiple functions, includ-
ing receptor binding and the ability to induce apoptosis of
CD8+ [5] (and occasionally CD4+) T cells. The A subunit
(LT-A) is noncovalently linked to LT-B by a trypsin-sensitive
loopand an α-helical regionthatjoins thetwo fragments[6].
LT-A has two subunits (A1 & A2) linked by a disulﬁde bond,
wherein the globular A1 subunit is enzymatically active and
the C-terminal A2 subunit is anchored into the pentameric
B subunit [7]. The A1 subunit contains an ADP-ribosylation
sitethatbindstoNAD+ andtransfers ADPribosetothealpha
subunitofGTP-bindingproteinsinvolvedinsignaltransduc-
tion. This leads to the activation of adenylate cyclase and
abnormal accumulation of intracellular cAMP, ultimately
leading to ﬂuid and electrolyte eﬄux from the cell, and the
watery diarrhea observed in the host [8]. The A1 subunits
of CT and LT were also found to bind ADP ribosylation
factors (ARFs)that are involved in the enhancement of ADP-
ribosylating activity [9]. Genetic fusion of foreign antigens
to the A2 portion of AB5 enterotoxins (of CT and LT),
in place of the A1, catalytic subunit has been shown to
be potent mucosal adjuvants and carrier proteins. Such
fusion proteins have been used to elicit mucosal immune
responses against the SBR from the streptococcal adhesin
AgI/II [10], the gonococcal transferring-binding proteins
TbpA and TbpB [11], and serine-rich Entamoeba histolytica
protein (SREHP, fused to a maltose-binding protein (MBP))
[12].
PE is a single-unit bacterial exotoxin which exhibits
NAD+-diphthamide ADP-ribosyl transferase activity, and
bindingofPEtoitsreceptor(α2-macroglobulinreceptor/low
density lipoprotein receptor-related protein (LRP1)/CD91)
initiates receptor-mediated endocytosis followed by the
exertion of its toxic eﬀects [13–16]. Fusion of an inactivated
form of this toxin (ntPE) with the V3 loop of HIV has
been shown to induce mucosal immune responses in vivo
[17, 18], indicating that such an approach may be useful for
vaccine design directed against mucosal pathogens. Previous
studies have indicated that the intranasal administration of
foot and mouth disease virus (FMDV) O1 BFS G-H loop
peptidesdonotinduceprotectiveimmuneresponsesincattle
[19]; however, the ntPE-GH fusion protein induced anti-G-
H serum IgG antibodies along with anti-ntPE serum IgG
and mucosal IgA antibodies when intranasally administered
to pigs [20], indicating that fusion proteins coupled to G-H
loop peptides could make useful mucosal vaccines.
The central hypothesis of this work is that an antigen,
suchastheFMDVG-Hloop,will inducerespiratory mucosal
immune responses against the epitope when genetically cou-
pled to the C-terminus of LT-B (where the toxic LT-A1
domain is replaced with the mucosal adjuvant ntPE) and
deliveredto animals through the nasal route.This hypothesis
is based on the observations that (1) a consensus G-H loop
peptide (administered parenterally) induced protection in
pigsuponviruschallenge [21],(2)mucosal immunization of
pigs through the nasal route has been shown to induce both
systemic IgG and nasal IgA antibodies [20], and (3) the G-H
loop antigen, when coupled to the mucosal adjuvant ntPE,
induced a modest immune response against the G-H loop
epitope when administered intranasally to pigs [20].
In the present study, we constructed the chimeric pro-
teins LTA2B-GH and ntPE-LTA2B-GH by inserting the cod-
ing sequence of the FMDV O1 BFS G-H loop onto the C-
terminus of LT-B. Inserting the G-H loop onto LT-B allows
ﬁve copies of the antigen to be displayed to the host’s
immune system as LT-B pentamerizes while fusing ntPE in
place of the toxic A1 moiety will allow additional receptor
targeting properties of the fusion protein. Both fusion
proteinswere evaluatedforantigenic display oftheG-H loop
and pentamerization of the LT-B subunit. We then evaluated
the mucosal immunogenicity of these two nontoxic chimeric
proteins against the FMDV G-H loop in guinea pigs and
found that they are capable of inducing antigen speciﬁc
secretory IgA immune responses in the respiratory tract of
immunized animals.
2.Materialsand Methods
2.1. Plasmid Construction. The LT-A2/LT-B (referred to as
LTA2B) fragment from the plasmid pEnt [22]w a sP C R
ampliﬁed andclonedintoan N-terminus His6 tagcontaining
expression vector, pET-28b(+) ( N o v a g e n ,E M D ,G i b b s t o w n ,
NJ), between restriction enzyme sites BamH1 and Sal1 using
the following primers: LTA2B-BamH1-F.P: GCC CGT TGC
GGA TCC G GGT GAT ACT TGT AAT GAG GAG and
LTA2B- Sal1-R.P: GCG AGC CGA GTC GAC GTT TTT CAT
ACT GAT TGC CGC. This resulted in the generation of
the plasmid pET-LTA2B. The G-H loop sequence from the
previously generated ntPE-GH construct [20] was ampliﬁed
by PCR and subcloned into pET-LTA2B at the 3  end of
the LTA2B gene, between restriction enzyme sites Sal1 and
Xho1 using the following primers: GH-Sal1-F.P: GCC CGT
TGC GTC GAC C G TT A TA G TA G AA A CG C GG T Ga n d
GH-Xho1-R.P: GCG AGC CGA CTC GAG CAG TGT GCG
AGC AAC TTT CTG. This resulted in the generation of the
plasmid pET-LTA2B-GH. ntPE from pIVEX-ntPE [20]w a s
PCR ampliﬁed and cloned into a N-terminus His6 tag con-
taining expression vector, pET-28b(+), between restriction
enzyme sites Nde1 and HindIII using the following primers:
ntPE-Nde1-FP: GCC CGT TGC CAT ATG GCC GAG GAA
GCC TTC GAC CTC and ntPE-HindIII-RP: GCG AGC
AGA AAG CTT CTT CAG GTC CTC GCG CGG CGG. This
resulted in the generation of the plasmid pET-ntPE.L T A 2 B -
GH from the construct pET-LTA2BGH was PCR ampliﬁed
and sub-cloned into pET-ntPE at 3  terminus of the ntPE
gene between the restriction enzyme sites HindIII and Not1
using the following primers: LTA2BGH-HindIII-F.P: GCC
CGT TGT AAG CTT GGT GAT ACT TGT AAT GAG GAG
and LTA2BGH-Not1-R.P: GCG AGC CGA CGC GGC CGC
CAG TGT GCG AGC AAC TTT CTG. This resulted in the
generation of the plasmid pET-ntPE-LTA2B-GH.
2.2. PCR. For each of the above experiments, 50μLP C Rr e -
action mixture was made by using 5%DMSO, 1μMo fe a c hAdvances in Virology 3
primer, 200μM of each nucleotide, 100ng DNA, 1X Pfu
Turbo DNA Polymerase reaction buﬀer, and 2.5U of Pfu
Turbo DNA Polymerase (Stratagene, La Jolla, Calif, USA).
The PCR reaction was carried out as follows: 94◦Cf o r2m i n ,
followed by 30 cycles of 94◦C for 30sec, 65◦Cf o r3 0 s e c ,
72◦C for 2min, and ﬁnally followed by elongated extension
at 72◦Cf o r7m i n .
2.3. Expression of Fusion Proteins. The constructs, pET-
LTA2B-GH and pET-ntPE-LTA2B-GH, were transformed
into Rosetta 2 (DE3) pLysS cells (Novagen) and plated on
50μg/mL kanamycin and 34μg/mL chloramphenicol con-
taining Lysogeny broth (LB) agar plates. Positive clones were
culturedin 25mLLB media containing 50μg/mL kanamycin
and 34μg/mL chloramphenicol for 16hr at 37◦Ci nas h a k e r
incubator. Cultures were then transferred to 475mLLB
media containing 50μg/mL kanamycin and incubated for
another 4hr on a shaker incubator until the optical density
at 280nm (OD280) of the cultures reached 0.5-0.6. Later,
protein synthesis was induced upon the addition of 1mM
IPTG, and cultures were incubated for 4hr at 37◦Ci na
shaker incubator. The cells were centrifuged at 2600× gf o r
10min, and the cell pellets were stored at −20◦Co v e r n i g h t .
The pellets were thenthawed, afterwhich 12mL ofCellyticB
reagent (Sigma-Aldrich, St. Louis, Mo, USA) and 20μLb e n -
zonasenuclease (Novagen)wereaddedandvortexeduntilthe
samples were no longer viscous, and then incubated at room
temperature (RT) for 10min. Solutions were then trans-
ferred to 35mL centrifuge tubes, and the inclusion bodies
were pelleted by centrifuging at 23,360× gf o r1 0m i nu s i n g
the Sorvall super T21 tabletop centrifuge. The soluble frac-
tions (supernatant) were saved, and inclusion bodies were
resuspended in 6mL of Cellytic B, and 300μLo f1 0m g / m L
lysozyme solution (Sigma) was subsequently added, vor-
texed,and incubatedatRTfor10min. Following incubation,
10mL of 1:10 Cellytic B was added and centrifuged at
16,000× g for 10min. The supernatant was discarded, and
inclusion bodies were washed with an additional 10mL of
1:10 Cellytic B. The washes were repeated three times, after
which the inclusion bodies were solubilized in 10mL of urea
buﬀer (8M urea in 50mM sodium phosphate, 0.3M NaCl
buﬀer at pH 8.0).
2.4. Puriﬁcation of Fusion Proteins. His-Select Ni+2 resin
(2.0mL; Sigma) was centrifuged in a 15mL Falcon tube at
200× g for 5min to remove ethanol. The resin was washed
once with 13mLdd H2O and equilibrated using 13mL of
urea buﬀer. The resin was then incubated with solubilized
inclusion bodies at RT for 1hr followed by centrifugation at
200× g for 5min, and the supernatant was discarded. The
resin was washed twice with 13mL of urea buﬀer and the
puriﬁed protein eluted by adding 10mL of elution buﬀer
(10M urea, 150mM imidazole) and incubated for 30min at
RT on a shaker.
2.5. SDS-PAGE. Samples were mixed with 2x Laemmli Sam-
ple buﬀer (Sigma) at a 1:1 ratio and boiled for 10min in a
water bath prior to electrophoresis on 4–20% acrylamide
gradient Ready Gel Tris-HCL (BIO-RAD) using SDS-run-
ning buﬀer (25mM Tris, 192mM glycine, 0.1% (w/v) SDS,
pH 8.3). Gels were stained with Bio-safe coomassie stain
(BIO-RAD), and then destained with distilled water to visu-
alize proteins.
2.6. Western Blot. Proteins were transferred from polyacryl-
amide gels onto a polyvinylidene diﬂuoride (PVDF) mem-
brane in transfer buﬀer (25mM Tris, 192mM Glycine, 20%
methanol, pH 8.3) for 1hr at RT using Mini-Trans Blot
system (Bio-Rad, Hercules, Calif, USA). The membrane was
then blockedfor 1hr at RT using 3% nonfat dry milk in PBS,
supplemented with 0.05% Tween 20 (PBST), washed 3 times
with PBST and probedwith a 1:1,000dilutionofpiganti-G-
H serum (hyperimmune antisera from pigs immunized with
the FMDV type O consensus G-H loop containing peptide
UBITh [21]) for 1hr at RT followed by washing 5 times with
PBST. The membrane was then incubated for 1hr at RT with
horseradish peroxidase-conjugated (HRP) goat anti-pig IgG
(Bethyl laboratories, Montgomery, Tex, USA) and washed 5
times with PBST, thereafter. Antibody binding was detected
with 3,3 ,5,5 -tetramethylbenzidine (TMB, substrate kit for
peroxidase, Vector laboratories, Burlingame, Calif, USA)u n t i l
suﬃcient staining was detected.
2.7. GM1 ELISA. 96-well polystyrene Immulon-4 HBX mi-
crotiter plates (Dynex Technologies, Chantilly, VA) were coat-
ed with 50μLo f1 0 μg/mL GM1 (monosialotetrahexosyl-
ganglioside, Sigma) or BSA (negative control), diluted in
coating buﬀer (0.05M Na2CO3 buﬀer, pH 9.6). Plates were
then tightly wrapped in Paraﬁlm (Pechiney plastic packaging,
Menasha, Wis, USA), incubated overnight at RT, then stored
at 4◦C until they were used. On the day of assay, plates
were washed three times with 200μLo fw a s hb u ﬀer (50mM
Tris, 0.14M NaCl, 0.05% Tween 20, pH 8.0) using a Bio-
TekELx-405platewasher(Winooski, Vt,USA)andincubated
with 100μL of blocking solution (50mM Tris, 0.14M NaCl,
1% BSA, pH 8.0) for 1hr at RT followed by washing three
times with wash buﬀer. Then 50μLo ft h ep r o t e i n s ,L T A 2 B -
GH, ntPE-LTA2B-GH, cholera toxin B subunit (CTB), TCA
peptide (a 53-mer peptide comprised of three FMDV O1
BFS strain epitopes, including a known VP4 T helper cell
epitope, VP1 site C, and VP1 site A epitopes, “TCA” refers
to the directionality of epitopes), and ntPE (20μg/mL) was
added to separate wells and incubated at RT for 2hr. The
plates were washed 5 times with wash buﬀer, followed by the
addition of 1:1,000 dilution of rabbit antibody to cholera
toxin (Virostat, ME), 1:5,000 dilution of rabbit antibody to
Pseudomonas exotoxin A (Sigma) or a 1:500 dilution of
pig antibody to consensus G-H peptide, in diﬀerent wells,
followed by incubation at RT for 1hr. The plates were then
washed 5 times with wash buﬀer and a 1:10,000 dilution
of either goat antipig IgG conjugated to HRP (Bethyl labo-
ratories) or goat antirabbit IgG conjugated to HRP (Bethyl
laboratories) w a sa d d e da n di n c u b a t e da tR Tf o r1h r .Aﬁ n a l
wash (5 times) was performed with wash buﬀer followed by
the addition of TMB substrate (KPL, Inc, Gaithersburg, Md,
USA) and stopped by adding 2N H2SO4.T h eﬁ n a lO Dw a s4 Advances in Virology
obtained at 450nm using a Bio-Tek EL-311 plate reader. The
net anti-ntPE/TCA peptide/CTB responses for each sample
were calculated by subtracting the mean OD of the BSA-
coatedwells fromthemeanODofspeciﬁcantigen-incubated
wells.
2.8. Animals. Forty-eight, female, two-week-old, Duncan-
Hartley guinea pigs (Elm Hill Labs, Chelmsford, Mass, USA)
were randomly divided into eight groups of six, corre-
sponding to the vaccination groups described in Table 1.
The guinea pigs were housed in environmentally controlled
rooms, and food and water were provided ad libitum.A l l
animal procedures were conducted in accordance with an
approved University of Connecticut IACUC protocol (No.
A07-025).
2.9. Guinea Pig Vaccinations and Procedures. Guinea pigs
were anaesthetized using aerosolized isoﬂurane (Baxter
Healthcare Co., Deerﬁeld, Ill, USA), with doses calculated
based on body weight. Groups were immunized with 100μg
of protein immunogen via the intranasal (i.n.) or subcuta-
neous (s.c.) route, as indicated in Table 1. The immuno-
gens tested included Ovalbumin (control), TCA peptide,
LTA2B-GH, and ntPE-LTA2B-GH. The ﬁrst four groups (I-
IV) received i.n. vaccinations while the other groups (V-
VIII) received s.c. vaccination with the MPL+TDM+CWS
Adjuvant system (Sigma) in a 1:1 ratio. All animals were
primed on day 0, and the i.n. vaccinated animals were
boosted at weeks 1, 2, and 3 with the protein corresponding
to their groups while the s.c. vaccinated animals received
a booster dose only at week 3 (Table 1). Dosages of all
vaccines (except for LTA2B-GH) were in a total volume of
200μL per guinea pig at 100μL/naris. The dosage of LTA2B-
GH was administered dropwise in a total volume of 400μL
per guinea pig at 200μL/naris. Sera and nasal washes were
collected from animals at biweekly intervals. Nasal washes
were collected by depositing, and then aspirating, 50μLo f
sterile PBS into each nostril. Blood was collected by cardiac
punctureusing 0.5c.c.syringesand storedinheparin-treated
tubes (IRIS International Inc, Westwood, Mass, USA) at RT
for clotting, then centrifuging at 1500×gf o r1 0 m i nt o
obtain sera. Animals were sacriﬁced at week six while under
sedation, upon intra-cardiac injection of Euthazol (1mg/Kg,
Virbac AH Inc., Ft. Worth, Tex, USA) prior to necropsy and
tissue collection.
2.10. Tissue Collection and Processing. The spleen and nasal
mucosae were harvested from three of six animals from each
group during necropsy. These tissues were washed in sterile
RPMI1640+L-Glutamine(CellGro,MediatechInc,Herndon,
Va, USA) and transferred to tubes containing complete
RPMI media (RPMI 1640 + L-Glutamine + 10% FBS +
100μg/mL streptomycin sulfate, and 100U/mL penicillin)
and placed on ice. The spleens were disaggregated using a
10mL syringe plunger in a Petri dish containing 10mL of
complete RPMI media, ﬁltered through 10mm nylon mesh,
and centrifuged for 10min at 4◦C, 500×g. To lyse RBCs,
5mL ofACKlysisbuﬀer (0.15M NH4Cl, 10mM KHCO3,
Table 1: Vaccination strategy for guinea pig experiment.
Group Priming
week
Boosting
week Route Dose Treatment
I 0 1,2,4 i.n. 100μgO V A
II 0 1,2,4 i.n. 100μgT C A P e p t i d e
III 0 1,2,4 i.n. 100μgL T A 2 B - G H
IV 0 1,2,4 i.n. 100μgn t P E - L T A 2 B - G H
V 0 3 s.c. 100μgO V A
VI 0 3 s.c. 100μgT C A P e p t i d e
VII 0 3 s.c. 100μgL T A 2 B - G H
VIII 0 3 s.c. 100μgn t P E - L T A 2 B - G H
0.1mM NaEDTA, pH 7.4) was added to the cell pellet, in-
cubated for 5min at RT, and centrifuged for 10min at
4◦C, 500×g. The cell pellet was then resuspended in 5mL
of complete RPMI. The nasal mucosal tissue was washed
three times in sterile media and then transferred into a
50mL Erlenmeyer ﬂask containing 20mL of RPMI/EDTA
(complete RPMI along with 5mM EDTA, pH 8), and gen-
tly stirred for 15min at room temperature. EDTA treat-
ment/centrifugation was repeated two or three times, until
the supernatant appeared clear. Residual EDTA was then
removed by washing in complete RPMI media. Cells were
then subjected to treatment with RPMI/collagenase (com-
plete RPMI along with collagenase type 2 at 200U/mL (Wor-
thingtonBiochemicalCorporation,Lakewood,NJ,USA))for
1hr with gentle stirring at RT to release nasal mucosal lym-
phocytes.Thecontentsoftheﬂask were thenﬁlteredthrough
a sterile 10mm nylon screen, and the ﬁltrate was centrifuged
at 500×gf o r1 0m i na t4 ◦C. The cell suspension was washed
to remove residual collagenase, and the ﬁnal pellet was resus-
pended in 5mL of ice-cold RPMI-10. Both spleen and nasal
mucosal lymphocytes were counted using a hemocytometer
following trypan blue staining. Cells were then diluted to
106 cells/mL in complete RPMI and held on ice until use. All
steps were performed under aseptic conditions.
2.11. TCA Peptide/LTA2B-GH/ntPE-LTA2B-GH Speciﬁc
ELISA. TCA peptide, LTA2B-GH and ntPE-LTA2B-GH spe-
cific IgG, IgM, and IgA antibodies in sera and nasal washes
were assayed using an indirect ELISA. 96-well polystyrene
Immulon-4 HBX microtiter plates (Dynex Technologies)
were coated with 50μLo fa1 0μg/mL solution of either TCA
peptide, LTA2B-GH, ntPE-LTA2B-GH, or BSA (negative
control) in coating buﬀer (0.05M Na2CO3 buﬀer, pH 9.6),
tightly wrapped in Paraﬁlm (Pechiney plastic packaging),
incubated overnight at RT and then stored at 4◦Cu n t i l
needed. Plates were washed three times with 200μLo fw a s h
buﬀer (50mM Tris, 0.14M NaCl, 0.05% Tween 20, pH 8.0)
using a Bio-Tek ELx-405 plate washer. Plates were then
incubated with 100μL of blocking solution (50mM Tris,
0.14M NaCl, 1% BSA, pH 8.0) for 1hr at RT followed by
washing three times with wash buﬀer. Serum samples and
nasal washes from weeks 0, 2, 4, and 6 were diluted at 1:50
and 1:4, respectively, in sample buﬀer (50mM Tris, 0.14MAdvances in Virology 5
NaCl, 1% BSA, 0.05% Tween 20, pH 8.0) to determine sera
IgG and nasal wash IgA antibodies. 50μL of each sample
was applied in duplicate to the microtiter plate on all TCA
peptide, LTA2B-GH, ntPE-LTA2B-GH and BSA-coated
wells. After 1hr of incubation at RT, the plates were washed
ﬁve times with wash buﬀer, followed by the addition of goat
antiguinea pig IgG antibody conjugated to HRP (Bethyl
laboratories) (at a dilution of 1:5,000 in sample buﬀer) or
rabbit anti-guinea pig IgA antibody (at a dilution of 1:1000
in sample buﬀer), and incubated for 1hr at RT. Plates were
then washed ﬁve times with wash buﬀer followed by the
addition of goat antirabbit IgG antibody conjugated to HRP
(Bethyl laboratories), diluted at 1:10,000 in sample buﬀer
and incubated for 1hr at RT. A ﬁnal wash was performed,
followed by the addition of TMB substrate (KPL, Inc,
Gaithersburg, Md, USA) for 20min at RT, and the addition
of 2N H2SO4 stop solution to terminate the reaction. The
ﬁnal OD reading was taken at 450nm with an EL-311
Bio-Tek plate reader (Winooski, Vt, USA). The net anti-TCA
Peptide/LTA2B-GH/ntPE-LTA2B-GH speciﬁc responses
for each sample were calculated by subtracting the mean
OD of the BSA-coated wells from the mean OD of speciﬁc
antigen-coated wells.
2.12. ELISPOT. To detect IgG and IgA antibody secreting
cells, Multiscreen-IP (0.45μM) 96-well plates (Millipore,
Bedford, Mass, USA) were used. Plates were prewetted with
200μL/well of 70% ethanol and rinsed with sterile PBST.
Plates were then coated with the following proteins: TCA
peptide, LTA2B-GH and ntPE-LTA2B-GH and BSA control
suspended in sterile coating buﬀer, and 50μL/well followed
by incubation at 4◦C overnight. Plates were then washed
twice with sterile PBST (200μL per well) after bringing the
plates to RT. Plates were then blocked with sterile blocking
solution(100μL/well for 1hr at RT) followed by washing the
p l a t eo n c ew i t hs t e r i l eP B S T ,2 0 0μL/well. 106 cells were then
suspended in 200μL RPMI 1640 and added to designated
wells and incubated in a 5% CO2 incubator at 37◦Cf o r
14–16hr. Plates were then washed ﬁve times with PBST
(200μL/well), followed by the addition of primary detecting
antibody (goat-anti-guineapigIgGHRPat1:5,000orrabbit
antiguinea pig IgA at 1:5,000 dilutions in sample buﬀer),
50μL per well and incubation for 2hr at RT. Rabbit-anti-
guinea pig IgA-coated plates were washed ﬁve times with
wash buﬀer, followed by the addition of goat antirabbit IgG
antibody conjugated to HRP (Bethyl laboratories, diluted
1:10,000 in sample buﬀer and incubated for 1hr at RT).
Plates were then washed ﬁve times with PBST, and TMB
substrate was added to develop the plates using a 3:2
ratio of TMB stock solution to hydrogen peroxide solution
(Vector Laboratories Inc.). Spots were counted manually
using a Lecia CME microscope (Lecia Microsystems, Wetzlar,
Germany).
3.Results
3.1. Generation, Expression, and Antigenicity of LTA2B-GH
and ntPE-LTA2B-GH. Inthisstudy, we generated,expressed,
and puriﬁed the fusion proteins LTA2B-GH and ntPE-
LTA2B-GH (which contain the mucosal adjuvants ntPE and
LTA2B) coexpressed with the VP1 G-H loop of FMDV
serotype O1 BFS as a model antigen for the elicitation of
mucosal immune responses in guinea pigs (Figures 1(a) and
1(b)).Theinsertionofallsequencesintoexpressionplasmids
wasconﬁrmedviascreeningcoloniesbyPCRforthepresence
ofntPE(1890bp),LTA2B(513bp),G-H(75bp),andLTA2B-
GH (588bp) (Figure 1(b)). All fusion proteins were highly
expressed in E. coli BL21 (DE3) pLysS inclusion bodies after
IPTG induction, as evidenced by thick bands in acrylamide
gels (data not shown). The antigenicity of the G-H loop
within the fusion proteins LTA2B-GH and ntPE-LTA2B-
GH was conﬁrmed by immunoblotting using hyperimmune
antisera from pigs immunized with the FMDV consensus G-
H loop peptide [21]. As anticipated, the G-H loop speciﬁc
polyclonal antibodies recognized bothLTA2B-GH and ntPE-
LTA2B-GH (Figure 1(c)). Upon boiling in the presence of
SDS, the B subunits of LTA2B-GH dissociated from each
other, resulting in a single major band of approximately
15kDa (monomeric form). The ntPE-LTA2B-GH revealed
two major bands of the expected 78kDa (LTA2-ntPE) and
15kDa (LTA2B-GH monomer) size fragments.
3.2. GM1 ELISA. A GM1 ELISA was performed to assess
binding capacity of LT-B-containing fusion proteins to this
ganglioside (structures shown in Figures 2(a) and 2(b)).
The TCA peptide and ntPE were not detected by the anti-
GH loop antibodies as they have no mechanism for binding
to GM1. Conversely, LTA2B-GH was immunoreactive with
anti-CTB and anti-G-H antibodies, conﬁrming that LTA2B-
GH was properly folded and had pentamerized. Although
ntPE-LTA2B-GH was not reactive to anti-CTB and anti-G-H
antibodies, itdidreact with anti-ntPE antibodies, illustrating
that the fusion protein (ntPE-LTA2B-GH) was able to bind
to GM1 (Figure 2(c)), ostensibly as a result of the properly
folded LTA2B-GH region of the fusion protein.
3.3. Antibody Responses to G-H Loop Peptide. The puriﬁed
LTA2B-GH & ntPE-LTA2B-GH fusion proteins, ovalbumin,
and TCApeptide were i.n. ors.c. administered to guinea pigs
as described in Materials and Methods (Table 1). The earliest
serum anti-G-H IgG responses that could be detected by
ELISAwereobservedatweek2intheanimalss.c.immunized
with the TCA peptide (Figure 3(b)) and at week 4 in TCA
peptide i.n. immunized animals (Figure 3(a)). The animals
which received the TCA peptide s.c. produced signiﬁcant
antipeptide IgG responses at weeks 2, 4 and 6, and the
animals that received the TCA peptide intranasally produced
signiﬁcantanti-peptideIgGresponsesatweek4,ascompared
to other treatment groups.
There were no anti-G-H immune responses in the group
that received either LTA2B-GH or ntPE-TA2B-GH subcu-
taneously (Figure 3(b)). However, the group that received
LTA2B-GH i.n. induced anti-G-H serum IgG at weeks 4
and 6. This trend was also seen in the group immunized
with ntPE-LTA2B-GH intranasally although results were not
statistically signiﬁcant.6 Advances in Virology
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Figure 1: Generation and expression of fusion proteins. (a) Strategy for generation of recombinant fusion proteins by cloning amplicons
from PCR reactions. (b) After construction a positive colony was selected (for each plasmid) and again screened for the presence of each
fragments(ntPE,LTA2B, LTA2B-GH andthe G-H loop) by PCR ampliﬁcation.(c)Upon expression by IPTG andnickel columnpuriﬁcation
of proteins from pET-LTA2B-GH, and pET-ntPE-LTA2B-GH, western blots were performed using anti-G-H loop hyperimmune serum.
Identiﬁed were proteins of approximately 15 and 78kDa, respectively.
Anti-G-H IgA antibodies in nasal washes were evident at
weeks 4 and 6 in guinea pigs receiving ntPE-LTA2B-GH or
LTA2B-GH i.n. (Figure 3(c)). However, the group that re-
ceived the TCA peptide intranasally did not show signiﬁ-
cant levels of anti-G-H immune responses, indicating that
adjuvanticity (in this case derived from the fusion pro-
teins) is essential to elicit mucosal immune responses to
the nonreplicating FMDV G-H loop antigen. None of the
tested antigens elicited detectable IgA antibody responses in
the nasal mucosae of animals immunized subcutaneously
(Figure 3(d)).
3.4. Antibody-Secreting Cells (ASCs) in Spleen and Nasal Mu-
cosa. At sacriﬁce, lymphocytes were puriﬁed from spleen
and nasal mucosae from 3 of 6 animals in each group to
enumerate the isotype-speciﬁc ASC by ELISPOT. In groups
thatreceivedtheTCApeptide,LTA2B-GH,andntPE-LTA2B-
GH s.c., approximately 10–15spots/million of anti-TCA
peptide IgG lymphocytes were observed in the spleen. In
addition,onlythegroupsthatreceivedLTA2B-GHandntPE-
LTA2B-GH had an observable number of anti-TCA peptide
IgG ASC’s in the nasal mucosa (Figure 4(a)), indicating
that the presence of a carrier protein and/or adjuvant is
necessary for the induction of antibodies against this peptide
in the respiratory tissues. Moreover, only the groups that
received LTA2B-GH and ntPE-LTA2B-GH i.n. produced IgA
ASC speciﬁc for the TCA peptide in the nasal mucosa of
inoculated animals (Figure 4(b)), again indicating that the
adjuvanticity of the fusion proteins is essential to produce
mucosal immune responses. Nodetectableanti-TCA peptide
lymphocyte responses could be measured in the spleens of
any of the i.n. immunized animals.Advances in Virology 7
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site A (the G-H loop). (c) GM1 ELISA to illustrate the pentamerization of LTA2B-GH and ntPE-LTA2B-GH. Microtiter plates were coated
with GM1 and incubated with CTB, TCA peptide, ntPE, LTA2B-GH, and ntPE-LTA2B-GH. Then they were tested with anti-G-H, anti-CTB
and anti-ntPE antibodies to illustrate the GM1-binding capacity of fusion proteins. ∗∗∗P value < 0.001 according to ANOVA and post-hoc
Tukey-Kramer multiple comparisontest.
4.Discussion
The overall goal of this work was to develop mucosal adju-
vants that are eﬃcacious in the respiratory tract of animals,
with the ultimate goal of inducing immunity to prevent
disease, limit viral replication, and preventthe establishment
of chronic subclinical infections (namely, carrier animals).
Here we provide evidence that a targeted fusion protein
based on LTA2B-GH or ntPE-LTA2B-GH elicits mucosal
humoral immune responses against an important FMDV
VP1 neutralizing epitope in guinea pigs. These fusion pro-
teins were shown to be highly eﬀectivemucosalimmunogens
which induced local antigen-speciﬁc antibody formation,
including anti-G-H loop IgA in nasal wash samples.8 Advances in Virology
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Figure 3: IgG and IgA antibody responses in serum and nasal wash samples. Pre- and postvaccination serum samples were collected every
other week forsix weeks from animalsvaccinated i.n. (a)or s.c. (b) andwere assayedforimmunogen(left to right: ovalbumin, TCA peptide,
ntPE-LTA2B-GH, LTA2B-GH) IgG responses by ELISA. Nasal washes were collected at the same time points and animals vaccinated i.n.
(c) or s.c. (d) were assayed for immunogen IgA responses by ELISA. X-axis represents time in weeks, that is, from 0 to 6 weeks. Y-axis
represents OD @ 450nm. Statistical analysis was performed using ANOVA and Tukey’s mean comparison test. Signiﬁcance determined by
(∗)r e p r e s e n t i n gP<0.05, (∗∗) P<0.01, and (∗∗∗) P<0.001.
Despite the advantages of eliciting mucosal immune re-
sponses to protect animals from infectious diseases, success
inthisﬁeldhasbeen limitedduetotheinductionoflowanti-
body titers, transient immune responses requiring multiple
doses of antigen, delayed induction of immune responses,
and ineﬃcient establishment of memory responses. Addi-
tionally, the stimulation of mucosal immune responses by
non-viable antigens is often ineﬃcient and may in some in-
stances result in immunological tolerance [23]. Nonetheless,
it is well established that coadministration of adjuvant
molecules such as the bacterial toxins CT, LT, PT, and
PE secreted by Vibrio cholerae, E. coli, Bordetella pertussis,
and Pseudomonas aeruginosa, respectively, can induce strong
mucosal immune responses and prevent the induction of
mucosal tolerance [1, 24]. Furthermore, genetic fusion of
nontoxic enterotoxins (as carriers) to antigens has been suc-
cessfully used in vaccination strategies against several path-
ogens [25–27], and the O1 G-H loop fused to CT-B has
even been shown to protect from FMDV in a suckling
mouse model of infection [28]. Our data are in accordance
with these studies while expanding the receptor-binding
repertoire of the fusion proteins beyond those of previously
designed chimeras. This increases the potential number of
species in which any one immunogen may be eﬃcacious
while further enhancing mucosal immunity in the respira-
tory tract of inoculated animals.Advances in Virology 9
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Figure 4: Enumeration of IgG and IgA antibody-secreting cells.
Spleen and nasal mucosae were collected from 3 of 6 animals from
each group at the conclusion of the study, and lymphocytes were
collected from these tissues to enumerate IgG (a) and IgA (b) anti-
body-secreting cells by ELISPOT. Y-axis represents number of ASC
per million cells collected.
We hypothesized that when the FMDV G-H loop is cou-
pled to the C-terminus of LT-B subunit, a total of ﬁve copies
will be displayed on a single targeting molecule, as the B sub-
unit of LT forms a pentamer. Also, given that the G-H loop is
genetically fused at only one end (LTA2B-GH), it would not
likely induce any conformational constraints on the antigen
or adjuvant and would properly present multiple copies of
the antigen to the immune system. Indeed, eﬃcacy was
demonstrated in the i.n. vaccinated groups receiving ntPE-
LTA2B-GH or LTA2B-GH (but not the TCA peptide) in
terms of antigen-speciﬁc secretory IgA production. Others
have successfully used similar vaccine/adjuvant approaches,
but with alternative fusion sites for the antigen on the
enterotoxin. Miyata et al. chemically fused the Plasmodium
vivax ookinete surface protein, Pvs25, to the N-terminus of
CT-B and generated a vaccine construct that induced an
immune response which blocked parasite transmission [29].
In another study, the adhesin gene of Helicobacter pylori was
fusedtotheA2subunitofCT(adhesin-CTA2B).Thisvaccine
construct enhanced both IgA and IgG production and pro-
tectedmany micefrom infection [30].While therehasbeen a
high degree of success with other enterotoxin/antigen fusion
vaccines, we considered another approach for delivery of the
antigen, that is, to genetically fuse the FMDV VP1 G-H loop
to the C-terminus of LTA2B and replace the toxic A1 domain
with the ntPE adjuvant at the N-terminus of the A2 segment
(ntPE-LTA2B-GH). Expression of bothLTA2B-GH and ntPE
on the same plasmid allowed the formation of holotoxin-like
chimeras and in this way both the adjuvanticity and carrier
properties of LT-B and ntPE could be exploited. Also, given
that LT binds a greater diversity of ganglioside receptorsthan
other bacterial toxins, it is likely that the targeting properties
of this chimeric protein (consisting of ntPE-LTA2B-GH or
LTA2B-GH) has advantageous immunogenic qualities over
nonchimeric fusion proteins (although this hypothesis was
not empirically studied in this work). This is supported
by data indicating that ntPE-LTA2B-GH induced higher
amounts of anti-G-H IgA antibodies in nasal wash samples
than LTA2B-GH alone, thus indicating that the use of ntPE
along with LTA2B has an added eﬀe c ta ti n d u c i n gi m m u n i t y
against the G-H loop antigen, likely by targeting APC’s via
binding of CD91 present on their surface.
Puriﬁedlymphocytesfrom spleenandnasal mucosawere
restimulated with antigen and groups of animals receiving
LTA2B-GH, and ntPE-LTA2B-GH i.n. had the most vigorous
mucosal IgG and IgA responses. These results support our
central hypothesis that fusion proteins of mucosal adjuvants
with nonreplicating antigens are capable of producing
mucosal immune responses; unfortunately, neutralization
assays performed on the guinea pig sera from week 6 against
FMDVindicated thatonlythegroup which received theTCA
peptide s.c. had high neutralizing titers (data not shown).
There may be three possible reasons for this: (a) G-H loop
that is conjugated to the C-terminus of the LT-B may not
expose immune cells to a neutralizing epitope (possibly due
to sterichindrance thatmight haveoccurred as a resultof the
complex nature of the fusion proteins), (b) the presentation
of the G-H loop is at an insuﬃcient quantity, or (c) the
fusionproteinsactuallytolerizedtheanimalstotheG-Hloop
antigen. The immunization regime of guinea pigs included
100μgeachoftheTCApeptide,ntPE-LTA2B-GH,orLTA2B-
GH, and it is noteworthy that the proportion of the G-H
loop is only10μga n d2 0μg in ntPE-LTA2B-GH and LTA2B-
GH, respectively. An increased dose of ntPE-LTA2B-GH and
LTA2B-GH may produce a more robust immune response,
but this was not examined in this study.
In summary, we have shown that mucosal application of
chimeric fusion proteins stimulated the production of anti-
peptide speciﬁc serum IgG and nasal IgA immune responses.
At present, it is unclear how ntPE-LTA2B-GH and LTA2B-
GHinducedtheimmuneresponses observedinthesestudies,
whether by facilitating the delivery of ﬁve copies of the G-
H loop or by enhancing the immune response through the
additive eﬀects of these adjuvants, or some combination of
both.Takentogether,these resultsare inkeepingwith studies10 Advances in Virology
indicating that genetic fusion of antigens with mucosal car-
rier/adjuvants is an eﬀective approach for inducing mucosal
immunity to nonreplicating antigens.
Acknowledgments
The authors would like to thank the University of Con-
necticut animal care staﬀ for their assistance with animal
husbandry. This work was supported by USDA (ARS) under
cooperative agreement 58-1940-5-520 to the UCONN Cen-
ter of Excellence for Vaccine Research. Any opinions, ﬁnd-
ings, conclusion,orrecommendations expressed in this pub-
lication are those of the author(s) and do not necessarily
reﬂect the view of the U.S. Department of Agriculture.
References
[1] N. Lycke,“ADP-ribosylating bacterial enzymesforthetargeted
controlofmucosaltoleranceandimmunity,”Annals oftheNew
York Academy of Sciences, vol. 1029, pp. 193–208, 2004.
[ 2 ]J .D .C l e m e n t s ,N .M .H a r t z o g ,a n dF .L .L y o n ,“ A d j u v a n t
activity ofEscherichia coli heat-labile enterotoxinand eﬀect on
the induction of oral tolerance in mice to unrelated protein
antigens,” Vaccine, vol. 6, no. 3, pp. 269–277, 1988.
[3] K. C. Bagley, S. F. Abdelwahab, R. G. Tuskan, and G. K. Lewis,
“An enzymatically active a domain is required for cholera-like
enterotoxins to induce a long-lived blockade on the induction
of oral tolerance: new method for screening mucosal adju-
vants,”Infection and Immunity, vol.71, no.12, pp. 6850–6856,
2003.
[ 4 ]R .R a p p u o l i ,M .P i z z a ,G .D o u c e ,a n dG .D o u g a n ,“ S t r u c t u r e
andmucosaladjuvanticity ofcholeraandEscherichia coliheat-
labile enterotoxins,” Immunology Today, vol. 20, no. 11, pp.
493–500, 1999.
[5] S. Arce, H. F. Nawar, M. W. Russell, and T. D. Connell, “Dif-
ferential binding of Escherichia coli enterotoxins LT-IIa and
LT-IIb and of cholera toxin elicits diﬀerences in apoptosis,
proliferation, and activation of lymphoid cells,” Infection and
Immunity, vol. 73, no. 5, pp. 2718–2727, 2005.
[ 6 ] T .K .S i x m a ,S .E .P r o n k ,K .H .K a l ke ta l . ,“ C ry s t a ls t r u c t u r eo f
a cholera toxin-releated heat-labile enterotoxin from E. coli,”
Nature, vol. 351, no. 6325, pp. 371–377, 1991.
[7] D. M. Gill and R. S. Rappaport, “Origin of the enzymatically
active A1 fragment of cholera toxin,” Journal of Infectious
Diseases, vol. 139, no. 6, pp. 674–680, 1979.
[8] J.Holmgren,“Actions of cholera toxinand the prevention and
treatment of cholera,” Nature, vol.292, no. 5822, pp. 413–417,
1981.
[9] J. Mossand M. Vaughan,“Structure and function of ARF pro-
teins. Activators of cholera toxin and critical components of
intracellular vesicular transport processes,” Journal of Biologi-
cal Chemistry, vol. 270, no. 21, pp. 12327–12330, 1995.
[10] M. Martin, G. Hajishengallis, D. J. Metzger, S. M. Michalek, T.
D. Connell, and M.W. Russell, “Recombinant antigen-entero-
toxin A2/B chimeric mucosal immunogens diﬀerentially
enhance antibody responses and B7-dependent costimulation
of CD4+ T cells,” Infection and Immunity,v o l .6 9 ,n o .1 ,p p .
252–261, 2001.
[ 1 1 ]G .A .P r i c e ,H .P .M a s r i ,A .M .H o l l a n d e r ,M .W .R u s s e l l ,a n d
C. N. Cornelissen, “Gonococcal transferrin binding protein
chimerasinducebactericidal andgrowthinhibitoryantibodies
in mice,” Vaccine, vol. 25, no. 41, pp. 7247–7260, 2007.
[12] F .S u lt an,L.L.J in,M.G .J ob ling,R .K .H olme s,andS.L.St an-
ley, “Mucosal immunogenicity of a holotoxin-like molecule
containing the serine-rich Entamoeba histolytica protein
(SREHP) fused to the A2 domain of cholera toxin,” Infection
and Immunity, vol. 66, no. 2, pp. 462–468, 1998.
[13] R. J. Mrsny, A. L. Daugherty, M. L. McKee, and D. J. FitzGer-
ald, “Bacterial toxins as tools for mucosal vaccination,” Drug
Discovery Today, vol. 7, no. 4, pp. 247–258, 2002.
[14] D. C. Smith, J. M. Lord, L. M. Roberts, E. Tartour, and L.
Johannes,“1stclassticketto classI:protein toxinsas pathﬁnd-
ers for antigen presentation,” Traﬃc, vol. 3, no. 10, pp. 697–
704, 2002.
[ 1 5 ]D .V .P a s t r a n a ,A .J .H a n s o n ,J .K n i s e l y ,G .B u ,a n dD .J .F i t z -
Gerald, “LRP1B functions as a receptor for Pseudomonas exo-
toxin,” Biochimica etBiophysicaActa, vol.1741,no.3, pp. 234–
239, 2005.
[16] M. Z. Kounnas, R. E. Morris, M. R. Thompson, D. J.
F i t z G e r a l d ,D .K .S t r i c k l a n d ,a n dC .B .S a e l i n g e r ,“ T h eα2-
macroglobulin receptor/low density lipoprotein receptor-
related protein binds and internalizes Pseudomonas exotoxin
A,” J o u r n a lo fB i o l o gi c a lC h em i s t ry ,vol.267,no.18,pp. 12420–
12423, 1992.
[17] R. J. Mrsny, A. L. Daugherty, C. M. Fryling, and D. J. Fitzger-
ald, “Mucosal administration of a chimera composed of Pseu-
domonas exotoxin and the gp120 V3 loop sequence of HIV-1
induces both salivary andserum antibody responses,” Vaccine,
vol. 17, no. 11-12, pp. 1425–1433, 1999.
[18] D. J. FitzGerald, C. M. Fryling, M. L. McKee et al., “Character-
ization of V3 loop-Pseudomonas exotoxin chimeras:candidate
vaccines for human immunodeﬁciency virus-1,” Journal of
Biological Chemistry, vol. 273, no. 16, pp. 9951–9958, 1998.
[19] L. L. Rodriguez, J. Barrera, E. Kramer, J. Lubroth, F. Brown,
and W. T. Golde, “A synthetic peptide containing the con-
sensus sequence of the G-H loop region of foot-and-mouth
disease virus type-O VP1 and a promiscuous T-helper epitope
induces peptide-speciﬁc antibodies but fails to protect cattle
against viral challenge,” Vaccine, vol. 21, no. 25-26, pp. 3751–
3756, 2003.
[20] S. Challa, R. Barrette, D. Rood, J. Zinckgraf, R. French, and
L. Silbart, “Non-toxic Pseudomonas aeruginosa exotoxin A
expressing the FMDV VP1 G-H loop for mucosal vaccination
of swine against foot and mouth disease virus,” Vaccine,v o l .
25, no. 17, pp. 3328–3337, 2007.
[21] C. Y. Wang, T. Y. Chang, A. M. Walﬁeld et al., “Eﬀective syn-
thetic peptide vaccine for foot-and-mouth disease in swine,”
Vaccine, vol. 20, no. 19-20, pp. 2603–2610, 2002.
[22] S. J. Geary, B. A. Marchlewicz, and R. A. Finkelstein, “Com-
parison of heat-labile enterotoxins from porcine and human
strains of Escherichia coli,” Infection and Immunity,v o l .3 6 ,n o .
1, pp. 215–220, 1982.
[ 2 3 ]J .M e s t e c k y ,Z .M o l d o v e a n u ,a n dC .O .E l s o n ,“ I m m u n er e -
sponse versus mucosal tolerance to mucosally administered
antigens,” Vaccine, vol. 23, no. 15, pp. 1800–1803, 2005.
[24] L. De Haanand T. R. Hirst,“Cholera toxin andrelated entero-
toxins: a cell biological and immunological perspective,”
Journal of Natural Toxins, vol. 9, no. 3, pp. 281–296, 2000.
[ 2 5 ] M .T o t r o v ,X .J i a n g ,X .P .K o n ge ta l . ,“ S t r u c t u r e - g u i d e dd e s i g n
and immunologicalcharacterization of immunogens present-
ingthe HIV-1gp120V3looponaCTB scaﬀold,”Virology,v o l .
405, no. 2, pp. 513–523, 2010.
[26] C.H.Shi,C.Cao ,J .S.Zhig,J .Li,andQ.J .Ma,“ Genefusionof
cholera toxin B subunit and HBV PreS2 epitope and the anti-
genicity of fusion protein,” Vaccine, vol. 13, no. 10, pp. 933–
937, 1995.Advances in Virology 11
[ 2 7 ]X .L i ,J .L .E r b e ,C .V .L o c k a t e l le ta l . ,“ U s eo ft r a n s l a t i o n a l
fusionoftheMrpHﬁmbrialadhesin-bindingdomainwiththe
cholera toxin A2 domain, coexpressed with the cholera toxin
B subunit, as an intranasal vaccine to prevent experimental
urinary tract infection by Proteus mirabilis,” Infection and
Immunity, vol. 72, no. 12, pp. 7306–7310, 2004.
[ 2 8 ]H .S o n g ,Z .W a n g ,D .Z h e n ge ta l . ,“ An o v e lm u c o s a lv a c c i n e
against foot-and-mouth disease virus induces protection in
mice and swine,” Biotechnology Letters, vol. 27, no. 21, pp.
1669–1674, 2005.
[29] T. Miyata, T. Harakuni, T. Tsuboi et al., “Plasmodium vivax
ookinete surface protein Pvs25 linked to cholera toxin B sub-
unit induces potent transmission-blocking immunity by in-
tranasal as well as subcutaneous immunization,”Infection and
Immunity, vol. 78, no. 9, pp. 3773–3782, 2010.
[30] B. O. Kim, S. S. Shin, Y. H. Yoo, and S. Pyo, “Peroral immu-
nization with Helicobacter pylori adhesin protein genetically
linked to cholera toxin A2B subunits,” Clinical Science,v o l .
100, no. 3, pp. 291–298, 2001.